Title: 177Lu-PSMA-617 radioligand therapy for lymph node metastatic prostate cancer

Biography:

Finn Edler von Eyben is specialist in internal medicine and oncology. He defended a thesis in Sweden 1983 and in Denmark 2005 He has worked as chief consultant for a department of Internal Medicine in Nuuk, Greenland, and as consultant in oncology at department of oncology, Tawam hospital, Abu Dhabi, the United Arab Emirates. He has published 145 research articles, and also published two books. According to Researchgate, he has had 2950 reads and 1641 citations of his publications.

finn113edler@mail.tele.dk

Abstract

¹⁷⁷Lu-PSMA-617 radioligand therapy for lymph node metastatic prostate cancer

Finn Edler von Eyben

Center of Tobacco Control Research, Denmark

Patients with lymph node metastases of prostate cancer (LNM) appear to respond better to ¹⁷⁷Lu-prostate specific membrane antigen (PSMA)-617 radioligand therapy (RLT) than patients with end-stage prostate cancer. The present study aimed to analyze the outcome with ¹⁷⁷Lu-PSMA-617 RLT for a group of patients with LNM. In this multicenter study, we evaluated the antitumor effect and the safety of using ¹⁷⁷Lu-PSMA-617 RLT for 36 patients with LNM and 10 patients with LNM together with one or two bone metastases. Cumulative ¹⁷⁷Lu activity of ¹⁷⁷Lu-PSMA-617 RLT was median 14∙8 GBq (IQR 12∙0-20∙4). The largest lowering of PSA was median 86% (IQR 68-99). The patients did not develop grade 3-4 myelosuppression. During follow-up, 25 (54%) patients had PSA progression. 23 (50%) patients developed new metastases and one (2%) patient died of prostate cancer during follow-up. Patients with LNM and PSA before treatment <4 µg/L had a lower PSA after treatment with 177Lu-PSMA-617 RLT than patients with PSA before the treatment >4 µg/L (p=0∙001). Patients with Gleason score ≤8 had a better PSA progression-free survival than patients with Gleason score 9 (p=0∙027). Patients with LNM had a better PSA progression-free survival than patients with LNM combined with one and two bone metastases (p=0∙0003). In conclusion, the outcome with ¹⁷⁷Lu-PSMA-617 RLT for patients with recurrent LNM was markedly better for patients with Gleason score ≤8 and with LNM than for patients with Gleason score 9 and with LNM combined with one or two bone metastases.